Bio Impact Capital LLC Avadel Pharmaceuticals PLC Transaction History
Bio Impact Capital LLC
- $623 Million
- Q2 2024
A detailed history of Bio Impact Capital LLC transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Bio Impact Capital LLC holds 783,242 shares of AVDL stock, worth $12.1 Million. This represents 1.77% of its overall portfolio holdings.
Number of Shares
783,242
Previous 871,149
10.09%
Holding current value
$12.1 Million
Previous $14.7 Million
25.15%
% of portfolio
1.77%
Previous 2.41%
Shares
7 transactions
Others Institutions Holding AVDL
# of Institutions
13Shares Held
7.03MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA3.97MShares$61.4 Million8.25% of portfolio
-
Tri Locum Partners LP New York, NY1.19MShares$18.4 Million4.32% of portfolio
-
Knoll Capital Management, LLC Miami, FL600KShares$9.28 Million5.7% of portfolio
-
Knott David M Jr Syosset, NY333KShares$5.15 Million1.87% of portfolio
-
Schulhoff & CO Inc137KShares$2.12 Million0.93% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $937M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...